Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study

J Antimicrob Chemother. 2024 May 2;79(5):1045-1050. doi: 10.1093/jac/dkae071.

Abstract

Objectives: Staphylococcus epidermidis bone and joint infections (BJIs) on material are often difficult to treat. The activity of delafloxacin has not yet been studied on S. epidermidis in this context. The aim of this study was to assess its in vitro activity compared with other fluoroquinolones, against a large collection of S. epidermidis clinical strains.

Methods: We selected 538 S. epidermidis strains isolated between January 2015 and February 2023 from six French teaching hospitals. One hundred and fifty-two strains were ofloxacin susceptible and 386 were ofloxacin resistant. Identifications were performed by MS and MICs were determined using gradient concentration strips for ofloxacin, levofloxacin, moxifloxacin and delafloxacin.

Results: Ofloxacin-susceptible strains were susceptible to all fluoroquinolones. Resistant strains had higher MICs of all fluoroquinolones. Strains resistant to ofloxacin (89.1%) still showed susceptibility to delafloxacin when using the Staphylococcus aureus 2021 CA-SFM/EUCAST threshold of 0.25 mg/L. In contrast, only 3.9% of the ofloxacin-resistant strains remained susceptible to delafloxacin with the 0.016 mg/L S. aureus breakpoint according to CA-SFM/EUCAST guidelines in 2022. The MIC50 was 0.094 mg/L and the MIC90 was 0.38 mg/L.

Conclusions: We showed low delafloxacin MICs for ofloxacin-susceptible S. epidermidis strains and a double population for ofloxacin-resistant strains. Despite the absence of breakpoints for S. epidermidis, delafloxacin may be an option for the treatment of complex BJI, including strains with MICs of ≤0.094 mg/L, leading to 64% susceptibility. This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Drug Resistance, Bacterial
  • Fluoroquinolones* / pharmacology
  • France
  • Humans
  • Levofloxacin / pharmacology
  • Microbial Sensitivity Tests*
  • Moxifloxacin / pharmacology
  • Ofloxacin / pharmacology
  • Retrospective Studies
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Staphylococcus epidermidis* / drug effects
  • Staphylococcus epidermidis* / isolation & purification

Substances

  • Fluoroquinolones
  • Anti-Bacterial Agents
  • delafloxacin
  • Ofloxacin
  • Levofloxacin
  • Moxifloxacin